![](/img/cover-not-exists.png)
PRM118 - ADJUSTMENT FOR SUBSEQUENT THERAPIES RECEIVED: THE IMPACT ON OUTCOMES OF AN ECONOMIC MODEL OF NIVOLUMAB+IPILIMUMAB IN FIRST LINE RENAL CELL CARCINOMA
Cawston, H, Genestier, V, Dale, P, Doan, J, Malcolm, BVolume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.2238
Date:
October, 2018
File:
PDF, 370 KB
english, 2018